V Dipasquale1, S M C Gramaglia1, M A Catena1, C Romano1. 1. Unit of Pediatrics, Department of Human Pathology in Adulthood and Childhood "G. Barresi", University of Messina, Messina, Italy.
Abstract
WHAT IS KNOWN AND STUDY OBJECTIVE: Infliximab is a widely used drug for treating inflammatory bowel disease (IBD). This drug is known to rarely cause pericarditis in adult populations. CASE SUMMARY: This report details the case of a 14-year-old boy with ulcerative colitis who developed pericarditis after a second infliximab infusion. After discontinuation of therapy, the patient's symptoms were resolved. WHAT IS NEW AND CONCLUSION: To our knowledge, this is the first reported paediatric case of pericarditis as a possible complication of infliximab therapy in IBD. Among infliximab-related delayed adverse reactions, cardiac complications should be monitored in the paediatric population.
WHAT IS KNOWN AND STUDY OBJECTIVE:Infliximab is a widely used drug for treating inflammatory bowel disease (IBD). This drug is known to rarely cause pericarditis in adult populations. CASE SUMMARY: This report details the case of a 14-year-old boy with ulcerative colitis who developed pericarditis after a second infliximab infusion. After discontinuation of therapy, the patient's symptoms were resolved. WHAT IS NEW AND CONCLUSION: To our knowledge, this is the first reported paediatric case of pericarditis as a possible complication of infliximab therapy in IBD. Among infliximab-related delayed adverse reactions, cardiac complications should be monitored in the paediatric population.
Authors: Giacomo Caio; Lisa Lungaro; Fabio Caputo; Maria Muccinelli; Maria Caterina Marcello; Eleonora Zoli; Umberto Volta; Roberto De Giorgio; Giorgio Zoli Journal: BMJ Open Gastroenterol Date: 2021-03
Authors: Ravi S Patel; Sai Rohit Reddy; Adiona Llukmani; Ayat Hashim; Dana R Haddad; Dutt S Patel; Farrukh Ahmad; Domonick K Gordon Journal: Cureus Date: 2021-03-20